• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Cosmos Health Inc. - Common Stock (NQ:COSM)

    0.2563 +0.0065 (+2.60%)
    Streaming Delayed Price Updated: 10:05 AM EDT, Jun 17, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Cosmos Health Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    15 16 Next >
    News headline image
    Cosmos Health Signs 2.86 Million-Unit Contract Manufacturing Agreement With Pharmex S.A. Across Three Dermatological Products
    From Cosmos Health Inc.
    Via GlobeNewswire
    Discover the most active stocks in Monday's session. ↗
    Via Chartmill
    News headline image
    Cosmos Health Provides Update on United States Portfolio; Four 18 Series Products Introduced With Projected Annualized Revenue Over $22.7M and Approximately $17.0M Gross Profit
    Company at a Turning Point — Moving the Business to a Different Level, With Growing Revenue and a Roadmap Toward Improved Profitability 
    From Cosmos Health Inc.
    Via GlobeNewswire
    News headline image
    Cosmos Health Receives New Contract Manufacturing Orders Totaling 253,657 Units Across a Range of Medicines
    From Cosmos Health Inc.
    Via GlobeNewswire
    News headline image
    Cosmos Health Reports Annualized Sales Exceeding $1.5M for Its C-Scrub and C-Sept Antiseptic Brands in the UK and Greece; Plans EU Expansion Targeting $7.4M in Revenue and $5.3M in Gross Profit
    From Cosmos Health Inc.
    Via GlobeNewswire
    News headline image
    Cosmos Health Signs LOI to Acquire Doc Pharma S.A., a European GMP Pharmaceutical Manufacturer, a Transformative Step Expected to Boost Assets, Profitability, Production Capacity, and Product Portfolio
    From Cosmos Health Inc.
    Via GlobeNewswire
    News headline image
    Cosmos Health Secures Additional 180-Day Nasdaq Extension to Regain Bid Price Compliance
    From Cosmos Health Inc.
    Via GlobeNewswire
    News headline image
    $20 Million in Liquid Assets Support Rapid Growth Including Acquisitions, Bio Pharma Production and Nanotechnology Initiatives for Diversified Global Heath Leader Cosmos Health, Inc. (Nasdaq: COSM)
    Via Get News
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Cosmos Health Signs 3-Year Contract Manufacturing Agreement with Verisfield for 3.9 Million Units of VASCLOR GEST Progesterone Pessaries
    From Cosmos Health Inc.
    Via GlobeNewswire
    News headline image
    Cosmos Health CEO Issues Letter to Shareholders: Building an Innovative AI-Driven Global Healthcare Platform — Record Growth with U.S. Expansion Underway
    From Cosmos Health Inc.
    Via GlobeNewswire
    News headline image
    Cosmos Health Inaugurates State-of-the-Art Capsule Production Line with New 5-Year Contract Manufacturing Agreement with Provident Pharmaceuticals for 385,000 Units of CERTORUN
    From Cosmos Health Inc.
    Via GlobeNewswire
    News headline image
    Cosmos Health Completes Acquisition of Strategic Intellectual Property and Expands Nanotechnology Investment Initiatives
    Strengthening proprietary IP portfolio and next-generation product development pipeline 
    From Cosmos Health Inc.
    Via GlobeNewswire
    News headline image
    Cosmos Health Continues U.S. Expansion with Launch of Oliv18, Targeting Cardiovascular and Antioxidant Categories
    Science-backed, USDA and EU-certified, whole olive tree supplement for two major wellness categories — rapidly growing global market projected to exceed $33 billion 
    From Cosmos Health Inc.
    Via GlobeNewswire
    News headline image
    $65.3 Million Revenue in 2025 Followed by Q1 2026 Record of $17.9 Million with Momentum Continuing in Q2 for Diversified Global Heath Leader Cosmos Health Inc. (Nasdaq: COSM)
    Via Get News
    Topics Artificial Intelligence
    News headline image
    Cosmos Health Achieves Pan-European Distribution for Sky Premium Life Across All 27 EU Member States Through Leading E-Commerce Platform Skroutz
    From Cosmos Health Inc.
    Via GlobeNewswire
    News headline image
    Cosmos Health Identifies Approximately $20 Million in Non-Core Assets Available for Monetization to Accelerate Growth and Unlock Shareholder Value
    From Cosmos Health Inc.
    Via GlobeNewswire
    News headline image
    Cosmos Health Provides Balance Sheet Update: Highlights European Investment Bank Financing Discussions for up to €25M, Eliminates 38% of Warrant Overhang with No Dilution; Reaffirms Growth Trajectory; Notes No Known Business Reason for Recent Share Price
    From Cosmos Health Inc.
    Via GlobeNewswire
    News headline image
    Cosmos Health Enters $69 Billion Global Animal Health Industry with Veterinary C-Scrub Wash 4% Following Successful European Standard Testing Under EN 1656 and EN 1657
    From Cosmos Health Inc.
    Via GlobeNewswire
    News headline image
    Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029 — Building an Innovative, High-Margin Healthcare Platform with Strong Cash Generation
    From Cosmos Health Inc.
    Via GlobeNewswire
    News headline image
    Cosmos Health Announces Expiration of 4,874,126 Series B Warrants Unexercised; ~38% of Total Outstanding Warrants
    Via ACCESS Newswire
    News headline image
    Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion Underway
    Via ACCESS Newswire
    News headline image
    Cosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank (EIB) for the Financing of its €50M R&D Program; EIB Financing Represents up to 50%, or €25M, under the EIB's Venture Debt Program
    Via ACCESS Newswire
    News headline image
    Cosmos Health Announces Withdrawal of Registration Statement on Form S-1
    Via ACCESS Newswire
    News headline image
    Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months
    Via ACCESS Newswire
    News headline image
    Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed
    Via ACCESS Newswire
    News headline image
    Cosmos Health Introduces Fort18 in the United States - A Men's Sexual Stamina Supplement Expanding the 18 Series into Men's Wellness
    Via ACCESS Newswire
    News headline image
    Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months
    Via ACCESS Newswire
    Top movers in Friday's after hours session ↗
    Via Chartmill
    News headline image
    Cosmos Health Introduces the "18 Series" in the United States - A Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated Products
    Via ACCESS Newswire
    News headline image
    Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Product Portfolio
    Via ACCESS Newswire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    15 16 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.